Compass Therapeutics (CMPX) to Release Earnings on Thursday

Compass Therapeutics (NASDAQ:CMPX) is expected to release its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Compass Therapeutics to post earnings of ($0.10) per share and revenue of ($0.8180) million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 7:30 AM ET.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). On average, analysts expect Compass Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compass Therapeutics Stock Down 5.4%

Shares of NASDAQ CMPX opened at $1.85 on Thursday. The firm’s 50-day moving average price is $5.02 and its 200-day moving average price is $5.19. The company has a market cap of $332.26 million, a PE ratio of -4.50 and a beta of 0.79. Compass Therapeutics has a 52-week low of $1.61 and a 52-week high of $6.88.

Institutional Trading of Compass Therapeutics

Hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its holdings in Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares during the period. Xponance LLC bought a new stake in Compass Therapeutics during the fourth quarter valued at about $55,000. CIBC Bancorp USA Inc. bought a new stake in Compass Therapeutics during the third quarter valued at about $37,000. Creative Planning bought a new stake in Compass Therapeutics during the second quarter valued at about $30,000. Finally, Victory Capital Management Inc. grew its holdings in Compass Therapeutics by 20.6% during the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock valued at $44,000 after purchasing an additional 2,164 shares during the period. Institutional investors own 68.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Raymond James Financial downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 28th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Compass Therapeutics in a report on Thursday, March 12th. Jefferies Financial Group reaffirmed a “buy” rating and set a $9.00 price target on shares of Compass Therapeutics in a report on Thursday, March 5th. William Blair reaffirmed an “outperform” rating on shares of Compass Therapeutics in a report on Thursday, March 5th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Compass Therapeutics in a report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.60.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.